In the present study, the mean increases reported in weight, BMI, and waist circumference after 12 months were comparable in naive patients starting abacavir/ lamivudine/dolutegraviror tenofovir alafenamide/emtricitabine/bictegravir.
Weight gain in treatment-naive HIV-1 infected patients starting abacavir/lamivudine/dolutegravir or tenofovir alafenamide/emtricitabine/bictegravir / Calza L, Borderi M, Colangeli V, Miani T, Nuti B, Bon I, Lazzarotto T, Viale P. - In: AIDS. - ISSN 0899-9449. - STAMPA. - 36:1(2022), pp. 153-155. [10.1097/QAD.0000000000003063]
Weight gain in treatment-naive HIV-1 infected patients starting abacavir/lamivudine/dolutegravir or tenofovir alafenamide/emtricitabine/bictegravir
Calza L;Borderi M;Colangeli V;Miani T;Nuti B;Bon I;Lazzarotto T;Viale P
2022
Abstract
In the present study, the mean increases reported in weight, BMI, and waist circumference after 12 months were comparable in naive patients starting abacavir/ lamivudine/dolutegraviror tenofovir alafenamide/emtricitabine/bictegravir.File in questo prodotto:
Eventuali allegati, non sono esposti
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
